Navigation Links
Optimer Pharmaceuticals to Present at 20th Annual Credit Suisse Healthcare Conference
Date:11/1/2011

SAN DIEGO, Nov. 1, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the 20th Annual Credit Suisse Healthcare Conference on Thursday, November 10 at 10:00 AM Eastern Time (7:00 AM Pacific Time).

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

A live audio webcast of the presentation will be accessible on the Investors page of the Company's website at www.optimerpharma.com.  Replays of the presentation will be available at the same location for 30 days following the conference.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has developed and commercialized DIFICID™ (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adults 18 years of age or older with Clostridium difficile-associated diarrhea (CDAD). Optimer has filed a marketing authorization application with the European Medicines Agency for fidaxomicin. Optimer's clinical pipeline includes Pruvel™, a product in the fluoroquinolone class of antibiotics that has completed Phase 3 trials as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Contacts

Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
858-909-0736

Canale Communications
Jason I. Spark, Senior Vice President
619-849-6005


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2011 Financial Results
2. Optimer Pharmaceuticals to Present at the Canaccord Genuity Annual Growth Conference
3. Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
4. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
5. Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
6. Optimer Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals to Present at Oppenheimer Healthcare Conference
8. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
9. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
10. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
11. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... In contrast to traditional LED lights where the spectrum ... proprietary LED technology to incorporate their spectra in a ... critical in low proximity installations. The Valoya L-series offers ... which is up to four times longer than commonly ... was clearly higher when compared to traditional fluorescent or ...
(Date:12/19/2014)... San Diego, CA (PRWEB) December 18, 2014 ... announces a limited time special on Sartorius Biohit ... 1 Free on mLINE pipettes, Picus Electronic Pipette Trade-in ... recommended by Health and Safety officers around the world. ... repetitive manual pipetting. Other features include:, , ...
(Date:12/19/2014)... Egenix, Inc. is pleased to announce that Lionel Goldfrank ... succeed Donald Fresne ; Mr. Fresne has also resigned ... of the Board.  In recognition of the many contributions and ... twenty years, the Board designated Mr. Fresne as Chairman Emeritus. ... Search Committee to find a suitable replacement with Biotech industry ...
(Date:12/19/2014)... Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... pain, announced the results of its annual general meeting ... transformational year in Relmada,s history and it set the ... Sergio Traversa , chief executive officer of Relmada. ... financial, human resource and clinical development objectives that position ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2
... Clear Health Communication at the National Patient Safety ... Pfizer Health Literacy in Advancing Patient Safety Award. ... the Health Literacy field were Dr. Michael Wolf, ... at Northwestern University,s Feinberg School of Medicine, and ...
... study, EPA analysis indicate vast potential for POET,s cellulosic process ... ... Corn cobs are both economical and environmentally friendly as a feedstock ... for commercializing its new technology., , , , ,Removing corn cobs ...
... Inc. ("Sinobiopharma ", or "the Company") (OTC Bulletin ... has applied for two Chinese patents for its ... relaxant. The Company has applied to China,s State ... for Atracurium,s freeze-drying compounds (Application Number 200710127756.2; "Atracurium,s ...
Cached Biology Technology:Leaders in Health Literacy Recognized by the Partnership for Clear Health Communication at the National Patient Safety Foundation 2Leaders in Health Literacy Recognized by the Partnership for Clear Health Communication at the National Patient Safety Foundation 3Research Reinforces Economic, Environmental Benefits of Corn Cobs as Source for Cellulosic Ethanol 2Research Reinforces Economic, Environmental Benefits of Corn Cobs as Source for Cellulosic Ethanol 3Sinobiopharma Applies For Two Chinese Patents For Cisatracurium Besylate 2
(Date:12/17/2014)... Va. , Dec. 15, 2014 ... to make it easier to detect and prevent ... Today the agency started performing an ... capability will validate the authenticity of purchased microcircuits ... The new quality control measures will be conducted ...
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 16, 2014 ... has licensed its PerformTek biometric technology to industry leaders ... their highly accurate, clinically validated, biometric wearable products. These ... January 6-9 in Las Vegas . ... the technology is accurate, flexible and robust – with ...
(Date:12/17/2014)...  Automation is fundamentally transforming the travel experience ... international borders. Over the past decade, ePassports, biometric ... travelers to self process through border control via ... an increasing number of airports, seaports, and land ... to Maxine Most , Principal at Acuity ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2
... Manchester have made a surprising finding after studying how ... for research into human healing and regeneration. It ... regenerative capacities, in contrast to mammals, including humans. For ... one will regenerate within a week. For several years ...
... scientists, working with colleagues from Aix-Marseille University, have created a ... optical system and can analyse its components within minutes. This ... different materials. The breakthrough could allow for rapid ... could detect the presence of even trace amounts of a ...
... is available in Spanish . ... Agriculture (USDA) scientists are learning more about the movement ... actively feed on crop pests. Agricultural Research ... Agricultural Research Laboratory in Brookings, S.D., and former ARS ...
Cached Biology News:The secrets of a tadpole's tail and the implications for human healing 2The secrets of a tadpole's tail and the implications for human healing 3Graphene plasmonics beats the drug cheats 2Lady beetle diet influences its effectiveness as biocontrol agent 2
... Cassettes facilitate the hybridization of DNA or ... 25mm x 75mm glass slides. The proprietary ... correct for poor flatness, as is often ... low volume chamber (67uL analytical cavity volume) ...
... This reagent is formulated specifically for Alkaline ... high levels of activity for both the ... at final dilution. This product has ... providing the customer a longer shelf life, ...
... Lambda Free Light Chain ... of human immunoglobulin. Specificity: ... epitope of lambda chain. Reacts with ... lambda chains but not with lambda ...
... The SDSaway reagent is a valuable tool ... The presence of SDS in biological ... tightly bound SDS-protein complex, inhibits enzymatic activity ... presents as a contaminant in mass spectrometry ...
Biology Products: